The HTRA1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This heterogeneous pool carries targeted disruptions in the HTRA1 gene, resulting in loss of functional HTRA1 serine protease. As a polyclonal model, it enables population-level studies of HTRA1 deficiency without clonal biases.
The parental A-549 cell line, established from a 58-year-old Caucasian male with lung adenocarcinoma, exhibits an adherent epithelial morphology and serves as a model of alveolar type II epithelium. It is widely used for studies of respiratory infection, barrier function, and epithelial-mesenchymal transition (EMT). This host line retains lung adenocarcinoma features, providing a disease-relevant context for HTRA1 knockout research.
HTRA1 is a secreted serine protease that negatively regulates TGF-?? signaling by cleaving and inactivating TGF-??1 and TGF-??2 ligands. The HTRA1 gene is transcriptionally activated by p53 and induced under conditions such as oxidative stress, hypoxia, and DNA damage. HTRA1 also degrades multiple extracellular matrix (ECM) proteins, including fibronectin, decorin, and aggrecan, and its activity is modulated by the inhibitor protease nexin-1 (SERPINE2). In the absence of HTRA1, active TGF-?? ligands accumulate, bind the TGF-?? receptor complex (TGFBR1/2), and activate Smad2/3-mediated transcription. This signaling promotes expression of ECM components and EMT-associated genes, while also stabilizing ??-catenin and intersecting with Wnt/??-catenin signaling via Wnt3a. As a result, HTRA1 knockout cells exhibit enhanced TGF-??-driven cell migration, invasion, and ECM deposition.
Within the A-549 lung adenocarcinoma model, HTRA1 deletion recapitulates a tumor-permissive microenvironment driven by unchecked TGF-?? activity. This system enables detailed investigation of HTRA1??s tumor-suppressive functions, particularly its role in restraining EMT and metastatic behavior. The model is also relevant for studying the molecular basis of HTRA1-associated pathologies such as cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and age-related macular degeneration (AMD), where vascular and matrix abnormalities are prominent.
Typical research applications include western blotting to monitor HTRA1 and TGF-?? pathway markers (e.g., phospho-Smad2), RT-qPCR profiling of ECM genes and EMT transcription factors, TGF-??-responsive luciferase reporter assays, scratch wound migration and transwell invasion assays, immunofluorescence staining for E-cadherin and vimentin, TUNEL-based apoptosis detection, and in vitro ECM degradation assays. These cells are well-suited for high-throughput screening of TGF-?? pathway inhibitors and for proteomic identification of HTRA1 substrates. For technical inquiries or to discuss customized applications, please contact Ascent Research.
